<DOC>
	<DOCNO>NCT02195167</DOCNO>
	<brief_summary>Pediatric PK study SEP-225289 ( Dasotraline )</brief_summary>
	<brief_title>Dasotraline SEP360-105 Pediatric PK/PD Study</brief_title>
	<detailed_description>To characterize pharmacokinetics ( PK ) ass safety tolerability range single oral dos SEP-225289 subject 6 17 year old ADHD</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Subject , male female , must 6 17 year age , inclusive , time consent . Note : Subjects 17 year age time consent must birthday within follow 4 week order eligible study . Subject meet Diagnostic Statistical Manual Mental Disorders Fourth Edition ; Text Revision ( DSMIVTR ) criteria primary diagnosis ADHD ( inattentive , hyperactive , combine subtype ) establish comprehensive psychiatric evaluation review DSMIVTR criterion prior Screening . Diagnosis confirm Screening use Mini International Neuropsychiatric Interview Children Adolescents ( MINIKID ) . Subject 's parents/legal guardian must give write informed consent , include privacy authorization , prior study participation . The subject complete inform assent prior study participation . Note : Informed consent obtain parent unless one parent decease , unknown , incompetent , one parent legal responsibility care custody child . Subject subject 's parents/legal guardian must judge investigator willing able comply study procedure visit schedule , include venipuncture , overnight stay ( recommended parent/legal guardian remain overnight subject ) , followup visit . Subject , female , must pregnant breastfeeding , â‰¥ 8 year age must negative serum pregnancy test screening . Female subject childbearing potential male subject female partner childbearing potential must agree use effective medically acceptable form birth control throughout study period . Subject must general good health ( define absence clinically relevant abnormality determine investigator ) base screen physical neurological examination , medical history , clinical laboratory value ( hematology , chemistry , urinalysis ) . Note : If hematology , chemistry , urinalysis result within laboratory 's reference range , subject include investigator determines deviation clinically relevant . Subject within 3rd 97th percentile gender specific body mass index ( BMI ) forage World Health Organization ( WHO ) growth chart ( Appendix VI ) weigh least 25 kg . Subject must report history able swallow capsule . Subject subject 's parents/legal guardian must able fully comprehend informed consent/assent form , understand study procedure , able communicate satisfactorily investigator study coordinator . Subject parents/legal guardian daily commitment study would interfere attend study visit . Subject clinically significant unstable medical abnormality , chronic disease , history clinically significant abnormality cardiovascular , gastrointestinal , respiratory , hepatic , renal system , disorder history condition ( eg , malabsorption , gastrointestinal surgery ) may interfere drug absorption , distribution , metabolism , excretion . Subject history presence abnormal ECGs , investigator 's opinion clinically significant . Screening ECGs centrally overread , eligibility determine base overread report . Subject documented history Bipolar I II Disorder , major depression , conduct disorder , oppositional defiant disorder , generalize anxiety disorder ( obsessivecompulsive disorder ) history psychosis , primary focus treatment time 12 month prior screen . Subject organic brain disease , example , traumatic brain injury residuum , history febrile seizure . Subjects take anticonvulsant seizure control currently within past 2 year eligible study participation . Subject answer `` yes '' `` Suicidal Ideation '' item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) CSSRS Children 's Lifetime/Recent assessment screen . Subjects significant finding suicidal ideation upon completion CSSRS must refer investigator followup evaluation . Subject history attempt suicide . Subject tolerate venipuncture poor venous access would cause difficulty collect blood sample . Subject history severe allergies 1 class medication multiple adverse drug reaction . Subject history exposure stimulant intolerable side effect . Subject take antipsychotic medication within 8 week Visit 1 ( Screening ) . Subject take psychotropic medication , include healthfood supplement purported central nervous system activity ( eg , St. John 's Wort , melatonin ) , must washout equal minimum 5 half life medication prior Visit 2 . If half life medication unknown , example , herbal product , subject 28 day medication washout . Subject currently take antidepressant medication ( eg , bupropion , selective serotonin reuptake inhibitor [ SSRI ] / serotonin norepinephrine reuptake inhibitor [ SNRI ] , monoamine oxidase [ MAO ] blocker , tricyclic , etc ) . Subject subject 's family anticipate move outside geographic range investigative site study period , plan extend travel inconsistent recommend visit interval study duration . Subject history , current malignancy except non melanoma skin cancer . Subject positive screening test Hepatitis B surface antigen , Hepatitis C antibody , human immunodeficiency virus ( HIV ) 1 HIV2 . Subject participate investigational study within 30 day prior screen currently participate another clinical trial . Subject history substance abuse drug dependence ( exclude nicotine caffeine ) within 12 month prior screen , define DSM IV TR criterion positive urine drug screen ( UDS ) , cotinine test , breath alcohol test Visit 1 . Subject take disallowed medication chronic treatment . Subject experience significant blood loss within 60 day donate plasma within 72 hour prior Visit 1 intend donate blood undergo elective surgery within 30 day follow Visit 2 . Subject history allergic reaction know suspected sensitivity substance contain study drug formulation . Subject relative investigational site staff member . Subject , opinion investigator , unsuitable way participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>